← All trials
NCT07173803
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2025
- Primary completion
- Jul 31, 2029
- Completion date
- Jul 31, 2029
- First posted
- Sep 15, 2025
- Last posted
- Oct 7, 2025
- Enrollment
- 440
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- Harvard UniversityCollaborator
- University of California, San DiegoOfficial
- Harvard UniversityOfficial
- University of California, San DiegoCollaborator
- University of California, San FranciscoSponsor investigator
- Alzheimer's Clinical Trial Consortium (ACTC)Collaborator
- Alzheimer's Therapeutic Research InstituteCollaborator
- University of Southern CaliforniaCollaborator
- National Institute on Aging (NIA)Collaborator
- University of California, San FranciscoOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.